USPTO serial 79453486
1NHALER
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- TWOHIG, SHANNON MARIE
- Law office
- TMEG LAW OFFICE 105
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with 1NHALER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cosmetics; functional cosmetics; cosmetic powders; non-medicated cleansing agents for internal use; non-medicated cleansers for wellness purposes; non-medicated cleansers for personal use, namely, lung cleansers; cleansing sprays. | ACTIVE | — |
| 005 | Pharmaceutical preparations; drug delivery agents; pharmaceutical and chemical preparations for delivery through respiratory devices; pharmaceutical preparations and compounds for treating respiratory disorders, human allergies, anaphylaxis, fungal infections, viral infections, anxiety disorders, panic disorders, eating disorders, asthma, COPD, nicotine addiction, drug addiction, alcohol addiction, cystic fibrosis, depression, diabetes, epilepsy, erectile dysfunction, HIV, symptoms of menopause, migraines, motor neurone disease, symptoms associated with motor neurone disease, multiple sclerosis, myocardinal infarction, cardiac disorders, nausea, opioid abuse, pain, Parkinson's disease, pulmonary arterial hypertension, post-partum haemorrhage, sleeping disorders, malaria, cholera, diphtheria, anthrax, tetanus, hepatitis A, hepatitis B, influenza, measles, meningitis, polio, rabies, pneumonia, rotavirus, smallpox, typhoid, yellow fever, tuberculosis, lung cancer, cancers, chronic coughs, bronchitis, non-cystic fibrosis bronchiectasis, mucus buildup, obesity, cerebrovascular accidents and HPV; pharmaceutical preparations, namely rescue medications; pharmaceutical preparations, namely, antibiotics; pharmaceutical preparations, namely, nicotine replacement compounds; respiratory stimulants; pharmaceutical preparations for the treatment of respiratory, neurological, hormonal and immune system related diseases and disorders; biological preparations for medical purposes; antiserums for diagnostic purposes; diagnostic reagents and diagnostic markers for medical purposes in the fields of respiratory disorders, human allergies, anaphylaxis, fungal infections, viral infections, anxiety disorders, panic disorders, eating disorders, asthma, COPD, nicotine addiction, drug addiction, alcohol addiction, cystic fibrosis, depression, diabetes, epilepsy, erectile dysfunction, HIV, menopause, migraines, motor neurone disease, multiple sclerosis, myocardinal infarction, cardiac disorders, nausea, opioid abuse, pain, Parkinson's disease, pulmonary arterial hypertension, post-partum haemorrhage, sleeping disorders, malaria, cholera, diphtheria, anthrax, tetanus, hepatitis A, hepatitis B, influenza, measles, meningitis, polio, rabies, pneumonia, rotavirus, smallpox, typhoid, yellow fever, tuberculosis, lung cancer, cancers, chronic coughs, bronchitis, non-cystic fibrosis bronchiectasis, mucus buildup, obesity, cerebrovascular accidents and HPV; diagnostic reagents for medical purposes in the field of rescue medications; diagnostic reagents and contrast media for medical use; antibodies for medical purposes; assays for medical use; immune cells for medical purposes; antigen tests for use in the diagnosis and treatment of respiratory disorders, human allergies, anaphylaxis, fungal infections, viral infections, anxiety disorders, panic disorders, eating disorders, asthma, COPD, nicotine addiction, drug addiction, alcohol addiction, cystic fibrosis, depression, diabetes, epilepsy, erectile dysfunction, HIV, symptoms of menopause, migraines, motor neurone disease, symptoms associated with motor neurone disease, multiple sclerosis, myocardinal infarction, cardiac disorders, nausea, opioid abuse, pain, Parkinson's disease, pulmonary arterial hypertension, post-partum haemorrhage, sleeping disorders, malaria, cholera, diphtheria, anthrax, tetanus, hepatitis A, hepatitis B, influenza, measles, meningitis, polio, rabies, pneumonia, rotavirus, smallpox, typhoid, yellow fever, tuberculosis, lung cancer, cancers, chronic coughs, bronchitis, non-cystic fibrosis bronchiectasis, mucus buildup, obesity, cerebrovascular accidents and HPV; vaccine therapeutic preparations; homeopathic pharmaceuticals. | ACTIVE | — |
| 010 | Medical devices; inhalers; nasal inhalers; nasal sprays; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems; drug delivery systems; single use dry powder drug delivery device; metered dose drug delivery device; dry powder inhalers; medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for the treatment of respiratory disorders, human allergies, anaphylaxis, fungal infections, viral infections, anxiety disorders, panic disorders, eating disorders, asthma, COPD, nicotine addiction, drug addiction, alcohol addiction, cystic fibrosis, depression, diabetes, epilepsy, erectile dysfunction, HIV, symptoms of menopause, migraines, motor neurone disease, symptoms associated with motor neurone disease, multiple sclerosis, myocardinal infarction, cardiac disorders, nausea, opioid abuse, pain, Parkinson's disease, pulmonary arterial hypertension, post-partum haemorrhage, sleeping disorders, malaria, cholera, diphtheria, anthrax, tetanus, hepatitis A, hepatitis B, influenza, measles, meningitis, polio, rabies, pneumonia, rotavirus, smallpox, typhoid, yellow fever, tuberculosis, lung cancer, cancers, chronic coughs, bronchitis, non-cystic fibrosis bronchiectasis, mucus buildup, obesity, cerebrovascular accidents and HPV; inhalers for the treatment of respiratory disorders, human allergies, anaphylaxis, fungal infections, viral infections, anxiety disorders, panic disorders, eating disorders, asthma, COPD, nicotine addiction, drug addiction, alcohol addiction, cystic fibrosis, depression, diabetes, epilepsy, erectile dysfunction, HIV, symptoms of menopause, migraines, motor neurone disease, symptoms associated with motor neurone disease, multiple sclerosis, myocardinal infarction, cardiac disorders, nausea, opioid abuse, pain, Parkinson's disease, pulmonary arterial hypertension, post-partum haemorrhage, sleeping disorders, malaria, cholera, diphtheria, anthrax, tetanus, hepatitis A, hepatitis B, influenza, measles, meningitis, polio, rabies, pneumonia, rotavirus, smallpox, typhoid, yellow fever, tuberculosis, lung cancer, cancers, chronic coughs, bronchitis, non-cystic fibrosis bronchiectasis, mucus buildup, obesity, cerebrovascular accidents and HPV; drug delivery systems for nicotine replacement therapies; apparatus for the alleviation and treatment of breathing difficulties; apparatus for administering drugs by inhalation; drug delivery devices sold empty, namely inhalers; membranes for filtration for use with medical devices; respiratory sensors; sensors for medical use to gather human biometric data; measuring devices for medical use; parts and fittings for all the aforesaid goods. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 18, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 17, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 9, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 2, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |